Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sun Pharma Advanced Research Co (NSE:SPARC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sun Pharma Advanced Research Co's Enterprise Value for the quarter that ended in Mar. 2026 was ₹42,849 Mil.
Sun Pharma Advanced Research Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15,871 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co EV-to-EBIT Related Terms
Sun Pharma Advanced Research Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's EV-to-EBIT falls into.
Sun Pharma Advanced Research Co's current Enterprise Value is ₹76,067 Mil.
Sun Pharma Advanced Research Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15,871 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co (NSE:SPARC) has a EV-to-EBIT of 4.79 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sun Pharma Advanced Research Co and its competitors. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #61 out of 686 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Sun Pharma Advanced Research Co's EV-to-EBIT too high?
Sun Pharma Advanced Research Co's current EV-to-EBIT is 4.79. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Sun Pharma Advanced Research Co's value of 4.79 is 69.5% below this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #61 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #61 out of 686 companies for EV-to-EBIT. This places Sun Pharma Advanced Research Co in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.73. Sun Pharma Advanced Research Co's value of 4.79 is 69.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current EV-to-EBIT of 4.79 is 69.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current EV-to-EBIT is 4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹83.04, compared to a current price of ₹216.98 — trading 161.3% above its estimated fair value. The current EV-to-EBIT is 4.79 and 69.5% below the Drug Manufacturers industry median of 15.73. Sun Pharma Advanced Research Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current EV-to-EBIT is 4.79 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued.
The current stock price of ₹216.98 is trading 161.3% above its estimated GF Value™ of ₹83.04.
GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.
Key valuation signals for NSE:SPARC:
EV-to-EBIT: 4.79
GF Value™: ₹83.04 vs. price of ₹216.98 (161.3% above fair value)
Industry Position: 69.5% below the Drug Manufacturers median (#61 of 686)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
44GF Score
Get the complete analysis for NSE:SPARC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
